NETJETS
21.5.2024 15:11:26 CEST | Business Wire | Press release
For the 23rd consecutive year, NetJets, the global leader in private aviation, proudly announces its partnership with Art Basel. To highlight its commitment to the arts, NetJets will collaborate with French abstract artist Silvère Jarrosson to create a new art collection exclusively for NetJets that will be displayed at the Art Basel shows in Basel, Paris and Miami Beach.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521442854/en/
Silvère Jarrosson, credit Julien Benhamou
Born and raised in Paris, Jarrosson trained as a ballet dancer at the renowned Opera National de Paris at only 10 years old but transitioned into abstract painting a decade ago. His background in ballet is seen throughout his motion and fluidity while creating his works of art. Represented by contemporary art agency Studio Artera in Paris, Jarrosson is known for using his whole body to make his art – as he moves or ‘dances’ with the canvas to create his signature acrylic pieces.
At only 31 years of age, Jarrosson has received widespread praise and has had his work showcased globally. His art is featured in prestigious institutions such as the Villa Medici in Rome, the Unterlinden Museum in Colmar, the Lambert Collection in Avignon, the Crédit du Nord Collection, the Mobilier National and the Opera National de Paris, among others.
Jarrosson’s project created for NetJets, entitled “Inner Horizons”, offers Owners – the individuals and businesses who are clients of NetJets’ private jet ownership model – captivating insight into his world of poetic immersion, where his spectators become part of the creative inspiration for his shows and projects. His work will be featured in NetJets' exclusive area within the Collectors Lounge. Accessible only by Owners, it will offer a secluded space for guests to enjoy hospitality throughout the show week of Art Basel in Basel. The show aims to merge external travel experiences made possible by NetJets with inner travel experiences created by Jarrosson’s art.
Patrick Gallagher, President of Sales, Marketing & Service, commented: “We are delighted with this partnership. We admire the synergy from the movement Silvère uses to create his art pieces. His beautiful artwork truly moves observers who watch him paint. Despite coming from different industries, we align in our passion to both create and capture exceptional experiences for others. As many of our Owners are deeply interested in fine art, we believe this partnership will be both inspiring and exciting as Silvère’s career continues to flourish.”
Globally recognised for its revolutionary shared ownership business model, NetJets’ impeccable reputation spans more than 60 years and has reshaped how people fly private. NetJets proudly maintains and operates over 1,000 aircraft, grants access to more than 5,000 airports and employs over 8,300 private aviation professionals to deliver outstanding service.
About NetJets
Originally incorporated in 1964 as Executive Jet Airways, NetJets has been setting – and exceeding – industry standards for over 60 years. Today, NetJets is proud to be a Berkshire Hathaway company known for its unwavering commitment to safety and service. NetJets’ portfolio of distinctive companies, encompassing NetJets, Executive Jet Management, QS Partners and QS Security, offers a variety of customisable travel solutions, including shared ownership, lease and jet card options, aircraft management, private jet chartering, brokerage and acquisition services and specialised security services. This comprehensive suite of solutions is why so many of the world’s most discerning travellers choose NetJets generation after generation. It is also because NetJets has the largest, most diverse private jet fleet in the world, which grants anytime access to even the most remote destinations across the globe. To learn more about the leader in private aviation, visit netjets.com today.
About Studio Artera
Studio Artera is an art and talent agency based in Paris that supports the finest visual artists.
We represent artists and integrate art in all contexts by creating meaningful artistic collaborations with brands, companies, cultural institutions, and cities. Driven by the desire to reach an ever-wider audience through art, we build artistic narratives with our clients to inspire millions of people around the world.
Clients of Studio Artera include Louis Vuitton, Prada, Levi’s, Bombay Sapphire, the Hoxton Group, the City of Paris, Château Charmail, and Viva Technology.
To learn more about us, please visit www.studioartera.com
About Art Basel
Founded in 1970 by gallerists from Basel, Art Basel today stages the world’s premier art shows for Modern and contemporary art, sited in Basel, Miami Beach, Hong Kong, and Paris. Defined by its host city and region, each show is unique, which is reflected in its participating galleries, artworks presented, and the content of parallel programming produced in collaboration with local institutions for each edition. Art Basel’s engagement has expanded beyond art fairs through new digital platforms and initiatives such as the Art Basel and UBS Global Art Market Report. Art Basel’s Global Media Partner is The Financial Times. For further information, please visit artbasel.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521442854/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom